Feature | Heart Valve Technology | April 07, 2016

TAVR Better for Patients with Severe Aortic Stenosis

Intermediate-risk patients fare better with Sapien 3 TAVR versus open-heart surgery

PARTNER II, Sapien 3, TAVR superior to surgery, severe aortic stenosis, ACC 2016

April 7, 2016 — New data demonstrates that for aortic stenosis patients at intermediate-risk for open-heart surgery, transcatheter aortic valve replacement (TAVR) with the latest generation of balloon-expandable device is superior to surgery, resulting in better patient outcomes.

This study — conducted by researchers in the Perelman School of Medicine at the University of Pennsylvania, in partnership with Edwards Lifesciences, the Cardiovascular Research Foundation, and 50 centers across the United States and Canada — was presented at the American College of Cardiology  (ACC) 65th Annual Scientific Session in Chicago and simultaneously published online in The Lancet.

Aortic stenosis (AS), the narrowing of the aortic valve opening which restricts blood flow to the aorta, afflicts nearly 1.5 million people in the United States, with approximately 500,000 of them suffering severe aortic stenosis. While open-heart surgery has historically been the recommended treatment for AS, some patients at high or extreme risk are not considered good candidates.

TAVR is a minimally invasive procedure which repairs the aortic valve without removing the old, damaged valve. In this case, the aortic valve is replaced with the Sapien 3, a device inserted into the heart to help the aortic valve open properly. The Sapien 3 device was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of high-risk patients.

Researchers enrolled 1,078 patients with severe, symptomatic aortic stenosis who were classified as being intermediate-risk for open-heart surgery. This risk classification is determined based on a patient’s age, presence of other chronic disease and whether they have undergone previous surgeries, among other criteria. Using a pre-specified propensity-score analysis, one-year Sapien 3 outcomes were compared with one-year surgical outcomes from 944 intermediate-risk patients treated with surgery in the PARTNER II randomized trial.

“For patients with severe, symptomatic aortic stenosis, a substantial obstruction of the aortic valve, surgery is the gold-standard treatment,” said Howard C. Herrmann, M.D., FACC, MSCAI, John W. Bryfogle Professor of Cardiovascular Medicine and Surgery, director of Penn Medicine’s Interventional Cardiology Program and co-author on the study. “However, these results prove that use of the Sapien 3 is more beneficial for intermediate-risk patients, who may otherwise experience surgical complications. Ultimately, TAVR with Sapien 3 can help alleviate severe, symptomatic AS with a less invasive alternative to open-heart surgery, which is especially important given that the age of most patients is over 75 years.”

Data shows that patients who underwent TAVR instead of surgery have better one-year outcomes based on mortality and stroke.

“We have already evaluated the benefit of Sapien 3 for high-risk patients in a study that was published in the fall, and now we have data to support the advantage of using this device in intermediate-risk patients,” said Wilson Y. Szeto, M.D., an associate professor of cardiovascular surgery, chief of cardiovascular surgery at Penn Presbyterian Medical Center and co-author on the study. “The next step will be to investigate whether TAVR with Sapien 3 is the best option for low-risk patients, which could result in a new treatment paradigm for all patients with aortic stenosis.”

Funding for this trial was provided by Edwards Lifesciences.

The PARTNER II trial also found that intermediate-risk patients with severe, symptomatic aortic stenosis treated with TAVR using the Sapien XT device had similar two-year outcomes as those treated with open-heart surgery with respect to all-cause mortality and disability stoke.

Herrmann and Szeto have received speaking honoraria from Edwards Lifesciences.

For more information: www.thelancet.com

Related Content

Videos | ACC| April 03, 2017
DAIC Editor Dave Fornell takes a tour of some of the interesting new technologies from the vendor booths on the expo
ACC.17 late breaking trial presentations, ACC late-breakers,  American College of Cardiology late breaking studies
Feature | ACC| March 22, 2017
Here is a list of the American College of Cardiology (ACC) 2017 annual meeting late-breaking clinical trials presente
Siemens Sensis Vibe, hemodyanamics system

Siemens released the Sensis Vibe hemodyanamics system at ACC.16. The newer system offers better integration of cath lab data into cath lab reports and the electronic medical record (EMR).

Feature | ACC| April 25, 2016 | Jon Brubaker, MBA, RCVT, Tom Watson, BS, RCVT, and Sabrina Newell MS, RCS
There were several trends seen in new cardiovascular technologies showcased on the expo floor at the 2016 American...
Videos | ACC| April 25, 2016
MD Buyline market analyst Jon Brubaker explained the new technology and trends he saw on the show floor at ACC.16. 
Videos | ACC| April 25, 2016
Michael Jaff, M.D., medical director of Massachusetts General Hospital’s Fireman Vascular Center, explains the curren
Videos | ACC| April 15, 2016
DAIC Editor Dave Fornell takes a tour of some of the trends and interesting new technologies from the vendor booths o
Videos | ACC| April 15, 2016
MDbuyline clinical analyst Tom Watson, BS, RCVT, explains the new hemodynamic system technology trends at ACC.16.
ACC late breakers
News | ACC| February 09, 2016
The following are the late-breaking clinical trial presentations presented at the 2016 American College of Cardiology

Photo courtesy of Vital Images

News | ACC| December 22, 2015
December 22, 2015 — In 2015, results from the ITALIC and CvLPRIT trials, along with studies examining lifestyle facto
Videos | ACC| March 25, 2015
DAIC Editor Dave Fornell shares his picks of the most interesting new devices and advances in cardiovascular technolo
Overlay Init